ReviewCurrent treatment options in oncology2026
The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.
Review in Current treatment options in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementThe field of immunotherapy for unresectable soft tissue sarcomas (STS) is transitioning from a one-size-fits-all approach toward a precision immuno-oncology paradigm. The pronounced immunological heterogeneity among histological subtypes and the limited predictive capacity of traditional classification underscore the imperative for immune-based stratification. Approximately 20% of STS exhibit an immune-activated tumor microenvironment, characterized by robust cytotoxic T lymphocyte infiltration, B-cell enrichment, and tertiary lymphoid structures (TLS); these patients demonstrate significantly higher objective response rates to immune checkpoint inhibitors (ICIs) and may be prioritized for such therapy. TLS status could be incorporated into routine clinical decision-making as a robust immunological biomarker for treatment selection. For the majority of patients with TLS-negative, immunologically "cold" tumors, however, single-agent ICIs are insufficient. Combination strategies designed to remodel the immunosuppressive tumor microenvironment represent a promising approach: enhancing tumor immunogenicity through epigenetic modulators, improving antigen presentation via CD47/SIRPα blockade, and exploring dual-checkpoint blockade to overcome T-cell exhaustion. For translocation-associated sarcomas, where neoantigen generation is inherently limited, adoptive cell therapies targeting specific antigens represent a particularly promising avenue. Biomarker-driven basket or umbrella trial designs are paramount to efficiently identifying optimal combination regimens and improving overall survival outcomes for patients with unresectable disease.
Indexed as
Identifiers
42283889What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.